Women hospitalized to give birth who had COVID-19 also had higher rates of myocardial infarction, venous thromboembolism, preterm birth<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Jan. 20, 2021 (HealthDay News) — Among U.S. women hospitalized for childbirth, the rates of death and certain adverse events are increased among those diagnosed with COVID-19, according to a research letter published online Jan. 15 in JAMA Internal Medicine<\/em>.<\/p>\n Karola S. Jering, M.D., from Brigham and Women’s Hospital in Boston, and colleagues compared clinical characteristics and outcomes of women with and without COVID-19, who gave birth in the hospital between April 11 and Nov. 23, 2020. Data were included for 406,446 women hospitalized for childbirth; 1.6 percent had COVID-19.<\/p>\n The researchers found that pregnant women with COVID-19 were younger, more often Black and\/or Hispanic, and more likely to have diabetes and obesity compared with pregnant women without COVID-19. Of the 6,380 women with COVID-19 who gave birth, 98.9 percent were discharged to home and 3.3, 1.3, and 0.1 percent needed intensive care, needed mechanical ventilation, and died in the hospital, respectively. In-hospital mortality was significantly higher in women with versus without COVID-19 (141 versus 5.0 deaths per 100,000 women). Women with versus without COVID-19 had higher rates of myocardial infarction (0.1 versus 0.004 percent) and venous thromboembolism (0.2 versus 0.1 percent). The odds of preeclampsia and preterm birth were increased in association with COVID-19 (adjusted odds ratios [95 percent confidence intervals], 1.21 [1.11 to 1.33] and 1.17 [1.06 to 1.29], respectively), but stillbirth was not (adjusted odds ratio, 1.23; 95 percent confidence interval, 0.87 to 1.75). <\/p>\n “As studies investigating therapies for COVID-19 have largely excluded pregnant women, the data also underscore the importance of including this population in clinical trials of treatments and vaccine,” the authors write.<\/p>\n Several authors disclosed financial ties to the biopharmaceutical industry.<\/p>\n